← All indications
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
Subtype terms (6)
More specific conditions that are subtypes of Arthritis, Rheumatoid in the MeSH hierarchy.
- Caplan Syndrome
- Felty Syndrome
2 drugs approved
- Rheumatoid Nodule
2 drugs experimental
- Rheumatoid Vasculitis
- Sjogren's Syndrome
131 drugs (54 approved, 77 experimental)
- Still's Disease, Adult-Onset
15 drugs (10 approved, 5 experimental)
Drugs by status
Approved for this indication (67)
- baricitinib
- indomethacin
- iguratimod
- methotrexate
- wangbi
- infliximab
- nabumetone
- penicillamine
- naltrexone
- urea
- adalimumab
- anakinra
- azathioprine
- xin te mie
- meloxicam
- methylprednisolone
- sarilumab
- kunxian
- filgotinib
- tolmetin
- bucillamine
- hydroxychloroquine
- hydrocortisone
- celecoxib
- abatacept
- certolizumab pegol
- diflunisal
- yuxuebi
- flurbiprofen
- triamcinolone
- +37 more
Phase 4 trials (50)
- buprenorphine
- corticotropin
- bazedoxifene
- tramadol
- milnacipran
- diphenhydramine
- hyaluronidase (human recombinant)
- rofecoxib
- canakinumab
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- eldecalcitol
- secukinumab
- vitamin d3
- omeprazole
- denosumab
- entecavir
- alfacalcidol
- ergocalciferol
- simvastatin
- folic acid
- varicella zoster virus glycoprotein e antigen
- prednisolone
- etoricoxib
- ibandronate
- tacrolimus
- calcium
- silymarin
- tetanus toxoid
- upadacitinib
- roxithromycin
- +20 more
Phase 3 trials (78)
- ruxolitinib
- escitalopram
- clobetasol
- nitroglycerin
- hesperidin
- fish oil
- eprodisate
- tc99m-tilmanocept
- ramipril
- donepezil
- cilostazol
- minocycline
- actarit
- olokizumab
- misoprostol
- abacavir
- cinnamon
- norethindrone
- levocarnitine
- sirukumab
- elemental gold
- diosmetine
- lumiracoxib
- pioglitazone
- fedratinib
- sm03
- autologous mesenchymal stem cells
- ce-224535
- live, attenuated, dengue serotype 1, 2, 3, 4 virus
- tripterygium wilfordii
- +48 more
Phase 2 trials (247)
- gs-5718
- abt-981
- umbilical cord mesenchymal stem cells
- bgb-45035
- itacitinib
- maraviroc
- aldesleukin
- gdc-0853
- bbibp-corv
- cyclophosphamide
- autologous stromal vascular fraction
- Mizacorat
- hl237
- spy002
- ch-1504
- dnaj peptide
- sodium butyrate
- bimekizumab
- atacicept
- prt-2607
- niacin
- ask-8007
- ssr150106
- bms-817399
- acalabrutinib
- cr6086
- sildenafil
- 2-hoba
- colchicine
- tgaac94
- +217 more
Phase 1 trials (132)
- monalizumab
- lipopolysaccharide
- cantharidin
- potassium
- art-i02
- moxifloxacin
- bi 655064
- platelet-rich plasma
- TNB-486
- vitamin k
- simeprevir
- pit565
- bcma/cd19 dual-target car-t
- gsk3358699
- ia-14069
- pravastatin
- cfz533
- gadobutrol
- 68ga-bnota-prgd2
- repaglinide
- hydrochlorothiazide
- allorx stem cells®
- cigb-814
- pd-0360324
- btt-1023
- qls12010
- midazolam
- pexidartinib
- sol-116
- 18f ge-180
- +102 more
Other trials (64)
- boswellia serrata
- tetrandrine
- bromocriptine
- amino acids
- sumatriptan
- oxycodone
- bromfenac
- citalopram
- oligo fucoidan
- ketorolac
- corn
- hepatitis a vaccine, inactivated
- fatty acid
- qingkailing
- xinfeng
- sodium chloride
- peoniflorin
- zushima
- briakinumab
- mussel oil
- eletriptan
- butyrate
- guli
- calcitriol
- boldine
- lactobacillus rhamnosus
- raloxifene
- frovatriptan
- rizatriptan
- p-aminobenzoic acid
- +34 more
Organizations
Organization Involved with Phase 4 Indications (207)
- Flinders University
- Government of Finland
- Bassett Healthcare
- Gyeongsang University
- Centre Hospitalier Régional d'Orléans
- NHS Borders
- Nazilli State Hospital
- NHS Fife
- Vita-Salute University of Milano. Italy
- University of Massachusetts
- Central Hospital of Kanta-Hame
- CHINESE RHEUMATISM DATA CENTER
- Spanish Foundation of Rheumatology
- ZonMw: The Netherlands Organisation for Health Research and Development
- Pharma Consulting Group AB
- Korea University
- Chosun University
- Medac
- Orton Invalid Foundation
- Bangladesh Medical University
- Aga Khan University
- Reade Rheumatology Research Institute
- Feinstein Institute for Medical Research
- Centocor
- National Health and Medical Research Council, Australia
- Dong-A Pharmaceutical
- Kosin University
- Parexel
- Shanghai Pharmaceuticals Holding Co., Ltd
- New York University
- +177 more
Organization Involved with Phase 3 Indications (118)
- Nichi-Iko Pharmaceutical Co., Ltd.
- Can-Fite BioPharma
- University of Duesseldorf
- SinoMab Pty Ltd
- Royan Institute
- National Center for Complementary and Integrative Health (NCCIH)
- Aix-University of Marseille
- Tzu Chi University
- Sunovion
- Momenta Pharmaceuticals
- University of Zurich
- CAICI
- Chugai
- Centro Reumatologico Strusberg
- University of Barcelona
- Gema Biotech S.A.
- Horizon Pharma
- Shanghai University of Traditional Chinese Medicine
- CER San Juan
- Emergent BioSolutions
- Instituto Médico CER
- Pirogov Russian National Research Medical University
- Biothera
- Mitsubishi Tanabe
- GlaxoSmithKline
- University of Erlangen-Nuremberg
- Arthritis and Rheumatic Disease Specialties
- Taisho Pharmaceutical
- Shanghai Henlius Biotech
- AB Science
- +88 more
Organization Involved with Phase 2 Indications (138)
- Rigel Pharmaceuticals
- Abivax S.A.
- NovImmune SA
- Procter and Gamble
- University Hospital of North Norway
- Theramab LLC
- Arana Therapeutics Ltd
- OxyPharma
- Pharmagenix
- University of Cincinnati
- Future University in Egypt
- University of Bordeaux
- Cura Biotech LLC
- Beijing Sl Pharma Co Ltd
- National Eye Institute (NEI)
- Tianjin University of Traditional Chinese Medicine
- Biotectid GmbH
- Michigan State University
- University of Colorado
- Zhongyuan Union Stem Cell Bio-engineering Corporation
- Endocyte
- Camargo Pharmaceutical Services
- MedImmune
- BioStrategics Consulting Ltd
- Aix Scientifics
- Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
- Root Causes Medicine
- Aclaris Therapeutics, Inc.
- Baylor University
- Alloksys Life Sciences B.V.
- +108 more
Organization Involved with Phase 1 Indications (59)
- Biotie Therapies
- Futian People's Hospital
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Oryn Therapeutics, LLC
- Shahid Beheshti University of Medical Sciences
- University of Arizona
- Northwestern University
- Thermo Fisher Scientific
- Jilin University
- University of Calgary
- Innate Pharma
- Ambit Biosciences
- Fujian Medical University
- Seaview Jacksonville, LLC
- Russian Academy of Medical Sciences
- Five Prime Therapeutics
- Plexxikon
- University of Siena
- Hutchison MediPharma
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Sadat City University
- Bayer
- SGS Life Sciences
- OSE Immunotherapeutics
- AXIS Clinicals Limited
- Amneal Pharmaceuticals
- University of Groningen
- University of California, San Francisco
- Arthrogen
- University of Southern California
- +29 more
Organization Involved with Other Experimental Indications (32)
- ImmunoPharma AS
- Ronald J. Rapoport, MD
- University of Athens
- Anhui Medical University
- Bangor University
- Sohag University
- Tianjin Medical University
- Changhai Hospital
- Anhui College of Traditional Chinese Medicine
- Rheumatoid Arthritis Investigational Network
- Canadian Institutes of Health Research (CIHR)
- University of Antwerp
- Cornell University
- Xijing Hospital
- University of Manitoba
- Government of China
- Wellcome Trust
- NIFES
- Swedish Foundation for Strategic Research
- Shanxi Medical University
- National Institute of Nutrition and Seafood Research, Norway
- Physicians Committee for Responsible Medicine
- Free University of Brussels
- University of Wisconsin
- University of Indonesia
- Nuvo Research Inc.
- German Federal Ministry of Education and Research
- Zhejiang University
- University of Minnesota
- Osaka University
- +2 more